Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, DNTH, GOSS, COGT, AVBP, and represent 50.03% of Octagon Capital Advisors's stock portfolio.
- Added to shares of these 10 stocks: CDTX (+$29M), Bridgebio Oncology Therapeut (+$12M), KYMR (+$5.3M), ABVX, PEPG, GPCR, DNTH, OCUL, COGT, PHVS.
- Started 4 new stock positions in CDTX, Bridgebio Oncology Therapeut, PEPG, GPCR.
- Reduced shares in these 10 stocks: VRNA (-$32M), SPRY (-$24M), ATYR (-$19M), NUVB (-$19M), TRML (-$15M), TSHA (-$12M), TRVI (-$7.8M), MRUS (-$7.6M), MLTX (-$7.0M), CNTA.
- Sold out of its positions in ATYR, ERAS, KLRS, MLTX, SPRY, TRML, VRNA, HLXB.
- Octagon Capital Advisors was a net seller of stock by $-90M.
- Octagon Capital Advisors has $660M in assets under management (AUM), dropping by 44.80%.
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 26 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 17.1 | $113M | +4% | 1.3M | 84.90 |
|
| Dianthus Therapeutics (DNTH) | 14.4 | $95M | +3% | 2.4M | 39.35 |
|
| Gossamer Bio (GOSS) | 6.8 | $45M | -7% | 17M | 2.63 |
|
| Cogent Biosciences (COGT) | 6.3 | $41M | +4% | 2.9M | 14.36 |
|
| Arrivent Biopharma (AVBP) | 5.5 | $36M | 2.0M | 18.45 |
|
|
| Ocular Therapeutix (OCUL) | 4.6 | $31M | +8% | 2.6M | 11.69 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 4.5 | $30M | -27% | 9.1M | 3.27 |
|
| Merus N V (MRUS) | 4.4 | $29M | -20% | 308k | 94.15 |
|
| Cidara Therapeutics Com New (CDTX) | 4.4 | $29M | NEW | 300k | 95.76 |
|
| Trevi Therapeutics (TRVI) | 3.9 | $26M | -23% | 2.8M | 9.15 |
|
| Mind Medicine Mindmed Com New (MNMD) | 3.8 | $25M | 2.1M | 11.79 |
|
|
| Apellis Pharmaceuticals (APLS) | 3.1 | $20M | 904k | 22.63 |
|
|
| Kymera Therapeutics (KYMR) | 3.1 | $20M | +35% | 360k | 56.60 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.1 | $20M | -19% | 830k | 24.25 |
|
| Pharvaris N V (PHVS) | 2.7 | $18M | +7% | 723k | 24.95 |
|
| Kalvista Pharmaceuticals (KALV) | 2.4 | $16M | 1.3M | 12.18 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.1 | $14M | 1.1M | 12.65 |
|
|
| Bridgebio Oncology Therapeut Com New | 1.8 | $12M | NEW | 1.0M | 11.58 |
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 1.5 | $10M | 1.0M | 10.00 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 1.5 | $9.7M | -65% | 2.6M | 3.70 |
|
| Maze Therapeatics (MAZE) | 0.7 | $4.6M | 178k | 25.93 |
|
|
| Neurogene (NGNE) | 0.7 | $4.4M | -16% | 252k | 17.33 |
|
| Unicycive Therapeutics Com New (UNCY) | 0.7 | $4.4M | 1.0M | 4.36 |
|
|
| Pepgen (PEPG) | 0.5 | $3.2M | NEW | 700k | 4.62 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.5 | $3.2M | NEW | 115k | 28.00 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.1 | $385k | -32% | 104k | 3.70 |
|
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2025 Q3 filed Nov. 14, 2025
- Octagon Capital Advisors 2025 Q2 filed Aug. 14, 2025
- Octagon Capital Advisors 2025 Q1 restated filed May 16, 2025
- Octagon Capital Advisors 2025 Q1 filed May 15, 2025
- Octagon Capital Advisors 2024 Q4 filed Feb. 14, 2025
- Octagon Capital Advisors 2024 Q3 filed Nov. 14, 2024
- Octagon Capital Advisors 2024 Q2 filed Aug. 14, 2024
- Octagon Capital Advisors 2024 Q1 filed May 15, 2024
- Octagon Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Octagon Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Octagon Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Octagon Capital Advisors 2023 Q1 filed May 15, 2023
- Octagon Capital Advisors 2022 Q4 filed Feb. 14, 2023
- Octagon Capital Advisors 2022 Q3 filed Nov. 14, 2022
- Octagon Capital Advisors 2022 Q2 filed Aug. 15, 2022
- Octagon Capital Advisors 2022 Q1 filed May 16, 2022